Key result
Admission blood glucose, not antecedent diabetes, is linked to ~5% higher 1-year mortality after AMI.
Why the study?
The relative association of admission blood glucose levels and antecedent diabetes on early and long-term survival after myocardial infarction was unclear.
Is admission blood glucose concentration a more powerful predictor of mortality after myocardial infarction than an established diabetes diagnosis?
Cohort (n=4,111)
No
Is admission blood glucose concentration a more powerful predictor of mortality after myocardial infarction than an established diabetes diagnosis?
Admission blood glucose is a stronger independent predictor of short- and long-term mortality after acute myocardial infarction than an established diagnosis of diabetes.
Answers are grounded in this paper and cite their sources.
May enhance post-MI risk stratification via admission glucose beyond diabetes history; leaves open whether targeting it improves outcomes.
OBJECTIVE: To explore the relative association of admission blood glucose levels and antecedent diabetes on early and long-term survival in a contemporary UK population of patients with ST elevation myocardial infarction (STEMI) and non-STEMI (NSTEMI). DESIGN: Retrospective cohort study based on the Myocardial Ischaemia National Audit Project dataset. SETTING: Tertiary care centre. PARTICIPANTS: 4111 (20.3% known diabetes) consecutive patients admitted with acute myocardial infarction (58.3% STEMI) between October 2002 and September 2008. PRIMARY AND SECONDARY OUTCOME MEASURES: All-cause mortality at 30 days and 1 year. The relative association of admission blood glucose and of antecedent diabetes with mortality was assessed using multivariate Cox regression analysis. Furthermore, we compared these relationships in patients with STEMI to those with NSTEMI. RESULTS: By 30 days and 1 year, 409 (9.9%) and 677 (16.5%) of patients died. After adjusting for covariates, diabetes did not show independent association with mortality at any time point, in the entire cohort (HR 30 days 0.93 (95% CI 0.63 to 1.38); 1 year 1.00 (0.77 to 1.30)) or in subgroups of STEMI (HR 30 days 1.03 (0.65 to 1.64); 1 year 1.08 (0.77 to 1.51)) and NSTEMI (HR 30 days 0.62 (0.26 to 1.50); 1 year 0.87 (0.56 to 1.36)). In contrast, after adjusting for covariates, admission glucose showed robust and independent association with mortality in the entire cohort (HR: 30 days 1.07 (1.04 to 1.10); 1 year 1.05 (1.03 to 1.08)), and in the subgroup of STEMI (30 days 1.07 (1.03 to 1.10); 1 year 1.07 (1.04 to 1.10)), and NSTEMI (HR 30 days 1.07 (1.00 to 1.14); 1 year 1.02 (0.97 to 1.06)). CONCLUSIONS: Admission glucose is strongly associated with mortality in all presentations of acute myocardial infarction (AMI), irrespective of established diabetes diagnosis. The increased risk is maintained up to 1 year. Future studies are required to assess the impact of active management of elevated blood glucose in improving mortality in individuals admitted with AMI.
No takes yet. Share an insight, caveat, or question.
Gholap et al. (2012) conducted a cohort in Acute myocardial infarction (STEMI and NSTEMI) (n=4,111). Admission blood glucose concentration vs. Antecedent diabetes diagnosis was evaluated on All-cause mortality at 30 days and 1 year (HR 1.05, 95% CI 1.03-1.08). Admission blood glucose concentration was independently associated with 1-year mortality after acute myocardial infarction, whereas antecedent diabetes was not.
Synapse has enriched 10 related papers. Consider them for comparative context: